Outcomes for oligometastatic head and neck cancer treated with stereotactic body radiotherapy: Results from an international multi-institutional consortium

Head Neck. 2023 Oct;45(10):2627-2637. doi: 10.1002/hed.27488. Epub 2023 Aug 21.

Abstract

Background: We report the results of an international multi-institutional cohort of oligometastatic (OMD) head and neck cancer (HNC) patients treated with SBRT.

Methods: Patients with OMD HNC (≤5 metastases) treated with SBRT between 2008 and 2016 at six institutions were included. Treated metastasis control (TMC), progression-free survival (PFS), and overall survival (OS) were analyzed by multivariable analysis (MVA).

Results: Forty-two patients with 84 HNC oligometastases were analyzed. The TMC rate at 1 and 2 years were 80% and 66%, with a median time to recurrence of 10.1 months. The median PFS and OS were 4.7 and 23.3 months. MVA identified a PTV point maximum (BED)10 > 100 Gy as a predictor of improved TMC (HR = 0.31, p = 0.034), and a cumulative PTV > 48 cc as having worse PFS (HR = 2.99, p < 0.001).

Conclusion: Favorable TMC and OS was observed in OMD HNCs treated with SBRT.

Keywords: SABR; SBRT; oligometastatic: head and neck cancer; radiation oncology.

Publication types

  • Multicenter Study

MeSH terms

  • Head and Neck Neoplasms* / etiology
  • Head and Neck Neoplasms* / radiotherapy
  • Head and Neck Neoplasms* / surgery
  • Humans
  • Lung Neoplasms* / secondary
  • Progression-Free Survival
  • Radiosurgery* / methods
  • Retrospective Studies
  • Treatment Outcome